Results 81 to 90 of about 2,886,292 (384)

Synergistic effect of phosphodiesterase 4 inhibitor and serum on migration of endotoxin-stimulated macrophages. [PDF]

, 2018
Macrophage migration is an essential step in host defense against infection and wound healing. Elevation of cAMP by inhibiting phosphodiesterase 4 (PDE4), enzymes that specifically degrade cAMP, is known to suppress various inflammatory responses in ...
Catherine Jin, S-L, Chuang, Tsung-Hsien, Conti, Marco, Ding, Shiau-Li, Hsiung, Te-Chih, Weng, Fu-Chun, Wu, Chin-Pyng, Yang, Jing-Xing   +7 more
core  

Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington’s disease [PDF]

, 2017
Huntington’s disease (HD) is a polyglutamine (polyQ) disease caused by aberrant expansion of the polyQ tract in Huntingtin (HTT). While motor impairment mediated by polyQ-expanded HTT has been intensively studied, molecular mechanisms for nonmotor ...
Akira Sawa, Amy Gathercole, Cramer, Duman, Eiki Takimoto, Elaine Huston, Fatemi, Hamburg, Harrison, Hideyuki Sasaki, Houslay, Huston, Kandel, Kazuhiro Ishii, Kelvin Kai-Wan Hui, Koko Ishizuka, MacKenzie, Mao, Masaru Kurosawa, Miles D. Houslay, Motomasa Tanaka, Nobuyuki Nukina, Nollet, Noriko Takashima, Ryo Endo, Sawamura, Seshadri, Seshadri, Sun-Hong Kim, Tyedmers, Yoko Nekooki-Machida, Yusuke Komi   +31 more
core   +2 more sources

Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies

Annals of Neurology, EarlyView.
Autosomal recessive cerebellar ataxias are disabling neurodegenerative genetic conditions affecting balance and coordination. Advancements in genomic testing have improved diagnosis, leading to a new focus on the development of targeted precision therapeutics addressing cellular, biochemical, and genetic disease mechanisms with a resulting emphasis on ...
Brent L. Fogel, Thomas Klopstock, David R. Lynch, Francesca Maltecca, Mayank Verma, Berge A. Minassian, Frances M. Platt, Débora Farina Gonçalves, Hélène Puccio, Andreas Roos, Matthis Synofzik   +10 more
wiley   +1 more source

Viagra releases the brakes on melanoma growth

Molecular & Cellular Oncology, 2017
Use of the phosphodiesterase 5 (PDE5) blocker sildenafil (Viagra) has been linked to an increased risk of melanoma. In a recent study we discovered a growth-promoting cGMP pathway in melanoma cells.
Robert Feil
doaj   +1 more source

Sildenafil in Infants and Children

Children, 2017
Pulmonary arterial hypertension (PAH) management has been transformed in recent times with the advent of cheap and effective diagnostic tools and therapy.
Larisa Simonca, Robert Tulloh
doaj   +1 more source

Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line [PDF]

, 2017
Phosphodiesterase 5A (PDE5A) specifically degrades the ubiquitous second messenger cGMP and experimental and clinical data highlight its important role in cardiac diseases.
Barbagallo, Federica, Campolo, Federica, Cardarelli, Silvia, Cornacchione, Marisa, DE ARCANGELIS, Valeria, DI GRAZIA, Antonio, Gianfrilli, Daniele, Giorgi, Mauro, Isidori, Andrea, Lenzi, Andrea, Monaco, Lucia, Naro, Fabio, Pellegrini, Manuela, Zevini, Alessandra   +13 more
core   +1 more source

Mechanochemical Strategies Applied to the Late‐Stage Modifications of Pharmaceutically Active Compounds

Angewandte Chemie International Edition, Accepted Article.
This review explores the potential of mechanochemistry in the late‐stage modification of active pharmaceutical ingredients (APIs), offering a comprehensive analysis of methods designed to transform structurally complex molecular scaffolds. By examining the scope, efficiency, and mechanistic aspects of these approaches, the review highlights protocols ...
Johanna Templ, Lars Borchardt
wiley   +1 more source

Erectile dysfunction - an update of current practice and future strategies [PDF]

, 2013
Erectile dysfunction (ED) is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse.1 Up to 150 million men worldwide suffer from ED and this figure is likely to double by the year 2025.2 A number
Kalsi, J, Muneer, A
core   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

Cancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group   +32 more
wiley   +1 more source

New in treatment of hyperactive bladder with urge urinary incontinence in women

Бюллетень сибирской медицины, 2012
The combination of α1 adrenoceptor blocking agent and phosphodiesterase  inhibitor of 5th type is efficient in treatment of women with hyperactive bladder and urge urinary incontinence, which was proved by the studies of urodynamic and microcirculation ...
A. I. Neimark, M. V. Razdorskaya, I. V. Snegiryov   +2 more
doaj   +1 more source